3920-40-9

Basic information

• Product Name: 1H-Pyrazole-3-carboxamide,4-amino-1-methyl-(9CI)
• Synonyms: 1H-Pyrazole-3-carboxamide,4-amino-1-methyl-(9CI);4-amino-1-methyl-1H-pyrazole-3-carboxamide(SALTDATA: FREE);4-Amino-1-methyl-pyrazole-3-carboxamide
• CAS NO: 3920-40-9
• Molecular Formula: C₅H₈N₄O
• Molecular Weight: 140.145
• Product Categories: AMIDE
• Mol File: 3920-40-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 355.1°C at 760 mmHg
• Flash Point: 168.6°C
• Appearance: /
• Density: 1.56g/cm³
• Vapor Pressure: 3.2E-05mmHg at 25°C
• Refractive Index: 1.695
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 1H-Pyrazole-3-carboxamide,4-amino-1-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazole-3-carboxamide,4-amino-1-methyl-(9CI)(3920-40-9)
• EPA Substance Registry System: 1H-Pyrazole-3-carboxamide,4-amino-1-methyl-(9CI)(3920-40-9)

Safety Data

• Hazardous Substances Data: 3920-40-9(Hazardous Substances Data)

Usage

General Description

1H-Pyrazole-3-carboxamide, 4-amino-1-methyl-(9CI), also referred to as 4-Amino-1-methyl-1H-pyrazole-3-carboxamide, is a chemical compound. Its molecular formula is C5H8N4O, and it has a molecular weight of 140.147g/mol. This chemical compound is included in the class of organic compounds known as aminopyrazoles, where one of its characteristic components is a pyrazole ring that is substituted at one or more positions by an amino group. This chemical is particularly used for synthesis and pharmaceuticals. Key features that define this compound include its ring structure and the presence of a carboxamide group.

InChI:InChI=1/C5H8N4O/c1-9-2-3(6)4(8-9)5(7)10/h2H,6H2,1H3,(H2,7,10)

Upstream product

• 3920-39-6 1-methyl-4-nitro-1H-pyrazole-3-carboxamide 
• 400877-57-8 1-methyl-4-nitro-1H-pyrazole-3-carboxylic acid methyl ester 

Downstream Products

• 1161375-01-4 N-(3-carbamoyl-1-methyl-1H-pyrazol-4-yl)-2-(3-methanesulfonyl-phenyl)thiazole-4-carboxamide 
• 1357086-83-9 5-{[(4-methoxy-phenyl)carbamoyl]amino}-8-(furan-2-yl)-2-methyl-2H-pyrazolo[3,4-e][1,2,4]triazolo[1,5-c]pyrimidine 

Relevant articles and documents

Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma

Harboring MYD88 L265P mutation triggers tumors growth through the activation of NF-κB by interleukin-1 receptor associated kinase 4 (IRAK4) in diffuse large B-cell lymphoma (DLBCL), highlighting IRAK4 as a therapeutic target for tumors driven by aberrant MYD88 signaling. Herein, we report the design, synthesis, and structure?activity relationships of imidazo[1,2-b]pyridazines as potent IRAK4 inhibitors. The representative compound 5 exhibited excellent IRAK4 potency (IRAK4 IC50 = 1.3 nM) and favorable kinase selectivity profile. It demonstrated cellular selectivity for activated B cell–like (ABC) subtype DLBCL with MYD88 L265P mutation in cytotoxicity assay. The kinase inhibitory efficiency of compound 5 was further validated by Western blot analysis of phosphorylation of IRAK4 and downstream signaling in OCI-LY10 and TMD8 cells. Besides, combination of compound 5 and BTK inhibitor ibrutinib synergistically reduced the viability of TMD8 cells. These results indicated that compound 5 could be a promising IRAK4 inhibitor for the treatment of mutant MYD88 DLBCL.

HYDROXYL PURINE COMPOUNDS AND USE THEREOF

Disclosed are a series of hydroxyl purine compounds and the use thereof as PDE2 or TNFα inhibitors, in particular, the compounds as shown in formula (I), or tautomers thereof or pharmaceutically acceptable salts thereof.

NITROGEN CONTAINING HETEROARYL COMPOUNDS

The invention is concerned with novel nitrogen-containing heteroaryl compounds of formula (I) wherein A1, A2, R1, R2, R3, R4, R5 and R6 are as defined in the descripti